Clinical Trial Update: Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) [Phase 2]

View source ↗

Summary

Clinical trial update for RP1 as a monotherapy and in combination with nivolumab (IGNYTE) in Phase 2 across several cancers; the study is currently active but n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Non-melanoma Skin Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• RP1
• nivolumab (nivolumab)

Snippet

Sponsor: Replimune, Inc. | Conditions: Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H) | Phase 2 | Status: ACTIVE_NOT_RECRUITING